Lyrical Asset Management LP Purchases Shares of 1,830,276 Henry Schein, Inc. (NASDAQ:HSIC)

Lyrical Asset Management LP acquired a new position in Henry Schein, Inc. (NASDAQ:HSIC) in the 4th quarter, Holdings Channel reports. The firm acquired 1,830,276 shares of the company’s stock, valued at approximately $126,655,000. Henry Schein comprises approximately 1.9% of Lyrical Asset Management LP’s holdings, making the stock its 26th biggest holding.

A number of other hedge funds have also made changes to their positions in HSIC. Smartleaf Asset Management LLC boosted its holdings in Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after acquiring an additional 143 shares during the period. CIBC Asset Management Inc lifted its position in shares of Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock worth $1,235,000 after purchasing an additional 169 shares in the last quarter. Metis Global Partners LLC boosted its stake in shares of Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock valued at $291,000 after purchasing an additional 187 shares during the period. Central Pacific Bank Trust Division grew its holdings in Henry Schein by 2.0% during the 4th quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company’s stock valued at $706,000 after purchasing an additional 200 shares in the last quarter. Finally, Sanctuary Advisors LLC lifted its holdings in Henry Schein by 5.0% in the 4th quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company’s stock worth $294,000 after buying an additional 203 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Trading Down 1.7 %

Shares of HSIC stock opened at $65.47 on Friday. Henry Schein, Inc. has a 1 year low of $63.00 and a 1 year high of $82.49. The firm has a market capitalization of $8.13 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84. The stock has a fifty day moving average of $73.96 and a two-hundred day moving average of $72.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter last year, the firm posted $0.66 earnings per share. Henry Schein’s revenue was up 5.8% compared to the same quarter last year. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Barrington Research reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. Wells Fargo & Company assumed coverage on shares of Henry Schein in a research note on Friday, February 14th. They set an “equal weight” rating and a $80.00 price objective on the stock. Finally, Jefferies Financial Group raised their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.